Fiche société
AC Immune SA
Traitements, essais et publications liés.
Traitements6programmes
Essais2liés
Publications0liées
SourceDBlocale
Traitements
6| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| [18F]ACI-19626 PET in TDP-43 ProteinopathiesDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Alzheimer, Sclérose latérale amyotrophique | Phase 1 | Traitement symptomatique | Netherlands | À vérifier |
| ACI-7104.056 at Dose AThe purpose of this study is to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson's disease. | Parkinson | Phase 2 | À vérifier | Germany, Spain, United Kingdom | À vérifier |
| ACI-7104.056 at Dose B (optional)The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson's disease. | Parkinson | Phase 2 | À vérifier | Germany, Spain, United Kingdom | À vérifier |
| ACI-7104.056 at Dose C (optional)The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson's disease. | Parkinson | Phase 2 | À vérifier | Germany, Spain, United Kingdom | À vérifier |
| [18F]ACI-19626 PET in TDP-43 ProteinopathiesDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 1 | Traitement symptomatique | Netherlands | À vérifier |
| ACI-7104.056 at Dose AThe purpose of this study is to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson's disease. | Parkinson | Phase 2 | À vérifier | Germany, Spain, United Kingdom | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| ACI-7104.056 at Dose A | Parkinson | Phase 2 | NCT06015841 | VacSYn — A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease | ACTIVE_NOT_RECRUITING |
| [18F]ACI-19626 PET in TDP-43 Proteinopathies | Sclérose latérale amyotrophique | Phase 1 | NCT06891716 | [18F]ACI-19626 PET in TDP-43 Proteinopathies | RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||